<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294643</url>
  </required_header>
  <id_info>
    <org_study_id>SERENADE trial</org_study_id>
    <nct_id>NCT02294643</nct_id>
  </id_info>
  <brief_title>Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study</brief_title>
  <acronym>SERENADE</acronym>
  <official_title>A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the SERENADE trial is to evaluate the safety and efficacy of sarpogrelate in
      patients with CKD or DM after DES implantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rates of stent failure after percutaneous intervention (PCI) have declined after
      introduction of the drug eluting stent (DES). However, chronic kidney disease (CKD) or
      diabetes mellitus (DM) still remains a strong clinical predictor of poor prognosis with DES.
      Sarpogrelate, a selective 5-HT2a receptor antagonist, has antiproliferative effects as shown
      by its reduction of neointimal hyperplasia and smooth muscle cell proliferation as well as a
      potent antiplatelet agent inhibiting of 5-HT-induced platelet aggregation. However, the
      efficacy and safety data for sarpogrelate in patients with CKD or DM are limited. We aimed to
      test whether sarpogrelate has beneficial effects in patients with CDK or DM treated with DES.

      The SERENADE trial is a multicenter, off-label, prospective, placebo-controlled randomized
      study to test the superiority of triple anti-platelet therapy (TAT; aspirin, clopidogrel and
      sarpogrelate) to the conventional dual antiplatelet therapy (DAT; aspirin and clopidogrel) in
      preventing late lumen loss 9 months after the index procedure in patients with CKD or DM. A
      total of 220 patients exhibiting coronary artery disease (CAD) with DM or CKD will be
      randomized to TAT or DAT (1:1 ratio) after DES implantation. Primary endpoint is late lumen
      loss at 9 months assessed by quantitative coronary angiography (QCA). Secondary efficacy
      endpoints are composites of major adverse cardiovascular events (MACE) including cardiac
      death, nonfatal myocardial infarction (MI), and target lesion revascularization. Secondary
      safety endpoints are major bleeding event and hepatic or renal impairments.

      The SERENADE trial will give insight whether adjunctive therapy with sarpogrelate is helpful
      for patients with high risk profiles such as CKD or DM after DES implantation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss measured by quantitative coronary angiography</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause deaths</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nonfatal myocardial infraction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target lesion revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major bleeding using the TMI bleeding classification</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatic impairments as measured by ncreased serum glutamyl oxaloacetic transaminase level or glutamyl pyruvic transaminase level increased more than threefold of the upper normal range</measure>
    <time_frame>12 months</time_frame>
    <description>increased serum glutamyl oxaloacetic transaminase level or glutamyl pyruvic transaminase level increased more than threefold of the upper normal range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal impairments as measured by increased microalbuminuria or decreased creatinine clearance</measure>
    <time_frame>12 months</time_frame>
    <description>increased microalbuminuria or decreased creatinine clearance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">220</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Renal Insufficiency, Chronic</condition>
  <arm_group>
    <arm_group_label>aspirin, clopidogrel &amp; sarpogrelate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the triple anti-platelet treatment group will receive aspirin 100mg, clopidogrel 75mg and sarpogrelate (AnplagÂ®, Yuhan Corporation, Seoul, South Korea) 100mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin, clopidogrel &amp; placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the dual anti-platelet group will receive aspirin 100mg and clopidogrel 75mg daily plus placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sarpogrelate</intervention_name>
    <arm_group_label>aspirin, clopidogrel &amp; sarpogrelate</arm_group_label>
    <other_name>Anplag</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <arm_group_label>aspirin, clopidogrel &amp; sarpogrelate</arm_group_label>
    <arm_group_label>aspirin, clopidogrel &amp; placebo</arm_group_label>
    <other_name>Astrix</other_name>
    <other_name>Aspirin protect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <arm_group_label>aspirin, clopidogrel &amp; sarpogrelate</arm_group_label>
    <arm_group_label>aspirin, clopidogrel &amp; placebo</arm_group_label>
    <other_name>Plavix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Sarpogrelate)</intervention_name>
    <arm_group_label>aspirin, clopidogrel &amp; placebo</arm_group_label>
    <other_name>sugar pill manufactured to mimic sarpogrelate tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptomatic CAD (including acute coronary syndrome) or positive stress test and a
             native coronary lesion (&gt;50% diameter stenosis by visual estimation on coronary
             angiogram and reference diameter &gt; 2.5 mm)

          -  AND CKD or DM patients

        Exclusion Criteria:

          -  if they had contraindication to aspirin, clopidogrel or sarpogrelate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>November 24, 2014</last_update_submitted>
  <last_update_submitted_qc>November 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Chief of Cardiovascular Center in Seoul National University Bundang Hospital</investigator_title>
  </responsible_party>
  <keyword>sarpogrelate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Sarpogrelate</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

